Evidence map›Paper›PMID 40481382›Full record

Observational studyJournal of general internal medicine2026

Prediction of Cardiovascular Risk Among People with HIV Using the PREVENT Equations Compared to the Pooled Cohort Equations.

Matthew S Durstenfeld, Megan M McLaughlin, Monica Gandhi, John Kornak, Alexis L Beatty, Priscilla Y Hsue

Abstract readObservational StudyComparative Study
In one paragraph

Observational study in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew S DurstenfeldDepartment of Medicine, University of California San Francisco, San Francisco, USA. matthew.durstenfeld@ucsf.edu.ORCID 0000-0002-7612-3352
Megan M McLaughlinDepartment of Medicine, University of California San Francisco, San Francisco, USA.
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, USA.
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, USA.
Alexis L BeattyDepartment of Medicine, University of California San Francisco, San Francisco, USA.
Priscilla Y HsueDivision of Cardiology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, USA.

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT · 1988 to 2026
$93.6M
MOLECULAR AND CELLULAR BASIS OF CARDIOVASCULAR DISEASET32HL007731 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian L Black · 1992 to 2026
$12.4M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDiseaseK24AI112393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y. · 2014 to 2024
$1.9M
Low Cardiorespiratory Fitness and Chronotropic Incompetence inHIV: Risk Factors, Cardiovascular Implications, and Exercise Training as TreatmentK23HL172699 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Durstenfeld · 2024 to 2026
$593k
National Institute of Allergy and Infectious Diseases 5K24AI112393National Institute of Allergy and Infectious Diseases 5P30AI027763National Institute of Allergy and Infectious Diseases 5R37AI098472NCATS NIH HHS UL1 TR001872NHLBI NIH HHS 5T32HL007731NHLBI NIH HHS K23 HL172699NHLBI NIH HHS K23HL172699NHLBI NIH HHS T32 HL007731NIAID NIH HHS K24 AI112393NIAID NIH HHS P30 AI027763NIAID NIH HHS R37 AI098472
6 · The paper itself

Abstract

backgroundPeople with HIV (PWH) are at elevated risk of atherosclerotic cardiovascular disease (ASCVD), and current risk prediction tools underestimate risk among PWH. The American Heart Association developed new risk prediction equations, Predicting Risk of cardiovascular disease EVENTs (PREVENT), which have not been studied among PWH.

objectiveTo compare predicted 10-year ASCVD risk using PREVENT with the pooled cohort equations (PCE) and the implications for statin recommendations among PWH.

designA cross-sectional observational study using real-world, electronic health records

participantsAll people with HIV ages 40 to 75 without cardiovascular disease at 23 primary care and HIV clinics affiliated with two health systems in San Francisco, California from 2019 to 2024 MAIN MEASURES: We compared predicted 10-year ASCVD using the PREVENT equations and the PCE. Then we considered implications of PREVENT for statin therapy using current guidelines. KEY

resultsAmong 3357 PWH (median 57 years old; 73% male,12% female, 15% transgender/nonbinary/nondisclosed; 20% Black and 25% Latino), 91% were on antiretroviral therapy and 86% had virologic suppression. Among 2853 PWH with complete data for both calculators, the median predicted risk was 7.7% (interquartile range (IQR) 3.7, 14.0) using the PCE and 3.3% (IQR 1.9, 5.4) using PREVENT. Predicted risk was lower for 97% of individuals using PREVENT. Using a 10-year ASCVD risk threshold of 5%, only 28.6% of PWH would be strongly recommended for statins with PREVENT compared to 67.3% with PCE. The difference in predicted risk between the two equations varied across sex and race/ethnicity.

conclusionsThe PREVENT equations predict lower 10-year ASVCD risk for PWH compared to the PCE, which underpredicts risk for PWH. Underprediction of ASCVD risk, which -using new guidelines -would translate to 58% fewer PWH strongly recommended for statins using PREVENT compared to PCE, has the potential to increase cardiovascular disease and worsen healthcare disparities among PWH.

Indexed as

Cardiovascular DiseasesHIV InfectionsAdultAgedCohort StudiesCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedRisk AssessmentHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID40481382
PMCPMC12855674

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.